Test of CD47-SIRPα Inhibitors on the Immune Microenvironment Colon Cancer

NCT ID: NCT05955196

Last Updated: 2024-10-09

Basic Information

• Recruitment Status: RECRUITING
• Total Enrollment: 115 participants
• Study Classification: OBSERVATIONAL
• Study Start Date: 2023-01-09
• Study Completion Date: 2027-01-09

Brief Summary

Our goal is to create novel CD47-SIRPα inhibitors using small molecules to reverse TAM-mediated immune suppression and restore anti-tumor immunity in CRCs. Our program uses structure-based drug design to create selective and potent small molecule inhibitors of SIRPα-CD47 to target the tumor microenvironment with greater efficacy and lower toxicity than CD47-targeting antibodies. .

In order to study the activity of CD47-SIRPα inhibitors on the immune microenvironment of tumors, we propose to use organoids derived from biopsies of patients with colon cancer. Tumoroids preserve the patient's tumor stroma (including myeloid cells) and provide an accurate in vitro model of complex tumor immune interaction for the evaluation of immunotherapies.

Conditions

Cancer of the Colon

Study Design

• Observational Model Type: CASE_ONLY
• Study Time Perspective: PROSPECTIVE

Interventions

BLOOD AND TUMOR

sampling of 24 ml of peripheral blood and samples of colon cancers with healthy tissue in parallel on the surgery piece

Intervention Type: PROCEDURE

Eligibility Criteria

Inclusion Criteria

• Patient over 18 years old
• Patient who has signed a consent to participate;
• Patient with metastatic or non-metastatic colon cancer, or recurrence of colon cancer for whom excision surgery has been proposed;
• Patient affiliated to a social security scheme, or beneficiary of such a scheme

Exclusion Criteria

• Patient who had emergency colon cancer surgery
• Person in an emergency situation or unable to express their consent.
• Adult subject to a legal protection measure (adult under guardianship, curatorship or safeguard of justice),
• Patient unable to submit to the medical follow-up of the trial for geographical, social or psychological reasons

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Institut Paoli-Calmettes

OTHER

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Cécile de CHAISEMARTIN, MD

Role: PRINCIPAL_INVESTIGATOR

Paoli Calmettes Institute

Locations

Institut Paoli Calmettes

Marseille, , France

Site Status: RECRUITING

Countries

France

Central Contacts

Dominique GENRE, MD

Role: CONTACT

drci.up@ipc.unicancer.fr

+33491223778

Facility Contacts

GENRE Dominique

Role: primary

Role: backup

drci.up@ipc.unicancer.fr

33 (0)4 91 22 37 78

Other Identifiers

MACROSWITCH-IPC 2021-083

Identifier Type: -

Identifier Source: org_study_id